{"analyses":[{"ciPctValue":"95","groupDescription":"Interim futility analysis alternative hypothesis based on the design specification that the 7+3+GO arm would have a 12% increase in CR rate.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0025","statisticalMethod":"Test of difference of proportions","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"203"},{"groupId":"OG001","value":"207"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"296"},{"groupId":"OG001","value":"300"}],"units":"Participants"}],"groups":[{"description":"A 21 day treatment cycle of Induction 7+3 with a 2nd 21 day cycle of the same for patients who did not achieve a complete remission during the first cycle of treatment","id":"OG000","title":"Ara-C+Daunomycin"},{"description":"A 21 day treatment cycle of Induction 7+3+G.O. with a 2nd 21 day cycle of the same for patients who did not achieve a complete remission (CR) during the first cycle of treatment","id":"OG001","title":"Ara-C+Daunomycin+Mylotarg"}],"paramType":"NUMBER","populationDescription":"Eligible patients who did not withdraw consent","reportingStatus":"POSTED","timeFrame":"After induction therapy was completed (1 or 2 months)","title":"Complete Remission","type":"PRIMARY","unitOfMeasure":"participants"}